LumiraDx Investor Presentation Deck

1 Key Targets and Workflow 98% sensitivity No culture confirmation Results in 8 minutes, with early call out starting 3 minutes 0 Fluorescence (R) Performance Feasibility D1 (1:20) m wood L 40000 bode 10000 E Strep A Molecular Program Demonstrates Feasibility to Achieve Target Sensitivity Group A Strep H M Cycles lumiraDx™ Fluorescence (R 0000 KOKK 20000 1 . IN D2 (1:200) Group A Strep I E Cycles 1 H Fluorescence(R) 10000 30000 # Sample Collection & Lysis D3 (1:2000) N D Group A Strep M 15 . - Fluorescence (8) ocol 24 Insert Strip & Add Sample D4 (1:20000) Group A Strep Copyright ©2020 Lumirax Ltd. All Rights Reserved. Worldwide D P Cycles 21 Dilution D1 (1:10¹) D2 (1:10²) D3 (1:10³) D4 (1:104) D5 (1:105) D6 (1:106) D7 (1:107) |||| Amplification LMDX qSTAR 8/8 8/8 8/8 8/8 0/8 0/8 0/8 On market POC MDX 3/3 3/3 3/3 2/3 0/3 0/3 0/3

View entire presentation